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| BACKGROUND
There is a consensus in the United Kingdom that the current system of providing cancer genetic testing through specialist genetics services does not have the capacity to meet the demand raised by advances in genomic medicine. 1 Genetic testing and the delivery of information about cancer predisposing genes for cancer patients will therefore increasingly need to take place in the oncology clinic. The findings from this study, investigating agreement and disagreement amongst oncology and genetics health professionals and service users about the information required by women with breast or ovarian cancer about BRCA1/BRCA2 testing, will be helpful in informing current and future clinical practice.
Several studies have investigated the information communicated during genetic counselling about BRCA1/BRCA2 variants. 2, 3, 4 Women with cancer have more unmet information needs following genetic counselling than women without cancer. 5 Women undergoing genetic testing shortly after diagnosis to facilitate treatment decisions prefer brief cancer risk information without statistics and hope-giving information about options to address the risks. 6, 7 There are differences in the approach, focus, and training of health professionals specialising in oncology and genetics that are likely to impact on the information communicated. Clinical genetics focuses the family and involves information exchange and the provision of support. 8 Oncology focuses on the individual 9 and initiation of treatment. Oncology health professionals are not always confident in genetic risk assessment, 10 may be concerned about causing distress by genetics referral, 11 are not always clear about who is responsible for making referrals, 12 and do not consistently refer patients even if they have been identified. [13] [14] [15] Clinical guidelines recommend pre-test genetic counselling to enhance patients' understanding of the implications of testing for themselves and their families and to enable informed consent. 16, 17 Not having pre-test and post-test counselling has been associated with negative outcomes 18 Post-test counselling with affected women has been shown to significantly increase the proportion of at risk relatives who make contact with a genetics service. 19 However, nongenetics health professionals ordering genetic tests in the United States frequently do not schedule a pre-test counselling session. 20 As the issues around genetic testing become increasingly complex, it will be important to develop tailored and streamlined protocols for pre-test and post-test counselling. This study aimed to investigate areas of agreement and disagreement between expert health professionals and service users about the messages required by affected women about BRCA1/ BRCA2 and the timing of communicating key messages.
2 | METHODS
| Design
The study design was a Delphi consensus exercise 21 with health professionals and service users who had expert professional or personal experience in this field. The Delphi consensus method involves several rounds of survey with a group of experts who anonymously respond and then receive feedback on the group response before being sent a subsequent survey to complete. The goal is to reduce the range of responses with a view to achieving consensus. 22 
| Developing the questionnaire
An earlier study 23 identified the information communicated during genetic counselling with affected women following identification of a pathogenic BRCA1/BRCA2 variant. A key message was defined as "information required by the individual with cancer in order to understand the risks, implications and options for themselves and their relatives and to decide on a course of action that is appropriate for them."
This definition was derived from the cognitive and behavioural aspects of the definition and published goals of genetic counselling 24 and refined, together with criteria to assist with focusing on the definition, in a pilot study with 8 expert genetics health professionals. The questionnaire was developed using the Qualtrics software and tested for comprehension, readability, and usability by a genetics health professional, an oncology health professional, and a service user (the study interest group). Approach was made by personal email and study information was provided. Return of the questionnaire was accepted as consent to take part.
| Participants
Service users were identified via UK voluntary organisations that provide support and information for BRCA1/BRCA2 carriers.
Potential participants who expressed an interest were telephoned to explain the study, determine eligibility, and answer any questions.
Eligible participants were sent a participant information sheet and consent form. Of the 16 service users, 5 were BRCA1 carriers and 11 were BRCA2 carriers. The mean age was 53 (range 43 to 69 years): 9 had breast cancer, 3 had ovarian cancer, and 4 had breast and ovarian
cancer. Two participants were tested immediately after diagnosis and 14 underwent testing after treatment. Ten participants were educated to degree level or above, 6 completed education between ages 16 and 18 (shown in S2). Sixteen participants completed the round 1 questionnaire, 14 completed round 2, and 12 completed round 3.
| Procedure
Ethics approval was granted. Data were collected between November 2013 and October 2014.
The questionnaire included information about the purpose of the study, the definition of a key message, and the information messages.
The data were analysed separately for each group. The questionnaire was amended at each round according to the data from the previous
round. An agreement level of ≥75% was selected. 26 At each round, messages agreed as key or not key were removed from circulation.
Remaining messages were recirculated up to 3 times or until agreement was reached. Messages that did not reach agreement were circulated together with the median score, range of responses, and summarised anonymised comments. The neutral option was removed after the first circulation of each message to increase positive or negative responses.
Participants were asked to decide if each message was key or not key using a 5-point Likert scale with options ranging from "a key message" to "not a key message." Messages with a definite response were scored higher than those with a less definite response to capture the extent of certainty about the message.
The first time a message was circulated, comments were invited on the wording of the message, the reasons for selection, and potential additional key messages. For feasibility, changes to wording and suggested additional messages were accepted when suggested by 2 or more participants or for consistency with other messages.
For messages assessed as key or probably key, participants were asked to decide whether the message should be communicated, before testing, once a pathogenic variant has been detected, at both times or at another time altogether. Each response was equally rated as 1.
| Analysis
The mean score and its standard deviation for each message at each round and for each group were calculated using these functions in 3 | RESULTS
| Key messages
Health professionals agreed on 34 key messages and 18 messages that were not key. There was no agreement about 11 messages. These messages are shown in full in S3.
Service users agreed on 35 key messages and 11 messages that were not key. There was no agreement about 17 messages. These messages are shown in full in S4.
Health professionals and service users agreed on 30 key messages. These key messages are shown in abbreviated form in Table 1 .
Seven of the key messages reached ≥95% agreement amongst both groups. These key messages are shown in full in Table 2 . Both groups agreed that 10 messages were not key. There was disagreement between the groups about 3 messages. These messages are shown in full in Table 3 .
There was agreement by 1 group only about 6 messages. Health professionals agreed that messages about the variant not "skipping a generation," male inheritance and the outcomes of diagnostic testing were key messages; there was no agreement amongst the service users about these messages. Service users agreed that messages about genetic testing and insurance, the risk of male breast cancer, and breast awareness were key messages; there was no agreement amongst the health professionals about these messages. These data are shown in S3 and S4. Identifying the side of the family at risk is important.
| Reaching agreement
A BRCA1/BRCA2 gene fault may explain the family history.
The fault is in the BRCA1/BRCA2 gene (specify).
Cancer is not inevitable for carriers.
Predictive testing is available for relatives once a fault has been detected.
Women at 50% risk of a BRCA1/BRCA2 gene fault are eligible for high-risk breast screening.
Inform all at risk relatives that genetic testing is available.
Discussing the implications and possible outcomes prior to testing is important.
The decision to be tested is up to each individual.
Female BRCA1/BRCA2 carriers with BC are at increased risk of further primary BC.
Female BRCA1/BRCA2 carriers with OC/FTC are at increased risk of BC.
Female BRCA1/BRCA2 carriers with breast cancer are at increased risk of OC/FTC.
Female BRCA1/BRCA2 carriers without cancer are at increased risk of breast cancer.
For female BRCA1/BRCA2 carriers, the risk of BC between ages 25 and 30 may be increased. Most of the risk occurs after age 30.
Female BRCA1/BRCA2 carriers without cancer are at increased risk of OC, FTC, and PPC.
For female BRCA1 carriers, the risk of OC before age 40 may be increased. Most of the risk occurs after age 40. For female BRCA2 carriers most of the risk occurs after age 45.
Male BRCA1/ BRCA2 carriers are at increased risk of PC. The risk is higher in BRCA2 than BRCA1.
RRM is an option for female BRCA1/BRCA2 carriers.
Breast reconstruction is an option after mastectomy.
RRM reduces the risk of BC (but a small risk remains).
Annual breast screening is available from age 30 for female BRCA1/BRCA2 carriers.
There are limitations to breast screening.
Ovarian screening is not yet effective or available. Women with symptoms should see their GP.
Once the risk of ovarian cancer starts to rise, RRBSO is an option for female BRCA1/BRCA2 carriers.
RRBSO reduces the OC/FTC risk (but a small risk of PPC remains).
RRBSO before the natural menopause may reduce the risk of primary BC by up to 50% in unaffected BRCA2 carriers. a BSO will result in menopause.
Genetic testing may provide helpful risk and management information for female BRCA1/BRCA2 carriers with cancer.
RRM or CM will reduce the risk of a new primary BC but will not reduce the risk of metastases from the initial cancer.
Abbreviations: BC, breast cancer; CM, contralateral mastectomy; FTC, fallopian tube cancer; OC, ovarian cancer; PC, prostate cancer; PPC, primary peritoneal cancer; RRBSO, risk-reducing salpingo-oophorectomy; RRM, risk-reducing mastectomy; GP, general practitioner.
a Wording amended to reflect challenges to earlier evidence.
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TABLE 2 Key messages (in full) agreed by ≥95% of health professionals and service users
The children of a person with a BRCA1/BRCA2 gene fault each have a 50% (1 in 2) risk of inheriting the gene fault.
Predictive (targeted) genetic testing is available for relatives once a BRCA1/BRCA2 gene fault has been identified. This will show whether or not the person has inherited the known faulty gene, and so predicts whether they might be at risk (this is called a predictive test).
Before having a genetic test it is important to discuss the implications and possible outcomes.
Breast cancer risk is increased for women without cancer who have a BRCA1/BRCA2 gene fault.
For women who have a BRCA1/BRCA2 gene fault, ovarian cancer (including fallopian tube and primary peritoneal cancer) risk is increased.
Risk-reducing mastectomy (surgery to remove the breasts to reduce the risk of cancer) is an option for women who have a BRCA1/BRCA2 gene fault.
Once the risk of ovarian cancer starts to rise, risk-reducing bilateral salpingo-oophorectomy (surgery to remove the ovaries and fallopian tubes to reduce the risk of cancer) is an option for women who have a BRCA1/BRCA2 gene fault. 
| Study limitations
This study did not address the specific information needs of unaffected women undergoing genetic testing, affected women undergoing treat- The small sample size and heterogeneity of the groups may limit generalizability of these findings.
| Clinical implications
The key messages identified in this study are not intended as a didactic list; some messages will not be relevant to all women and some women will want more or less information. However, the key messages do provide a guide for communicating with affected women about BRCA1/BRCA2 genes and are a reminder that some information considered key by health professionals may not be considered key by women with cancer and vice versa.
Health professionals need to remain up to date with changes that may affect the key messages and carefully explain the nuances of the messages. This is highlighted by the recent challenge to the evidence regarding breast cancer risk reduction associated with risk-reducing bilateral salpingo-oophorectomy. [36] [37] [38] Where time or the ability to assimilate information is limited, for example, for women undergoing testing to determine cancer treatment, the messages with the highest level of agreement provide a minimum set of key messages to communicate: dominant inheritance, the availability of predictive testing, the importance of pretest discussion, increased risk of breast and ovarian cancer, and the option of risk-reducing mastectomy and bilateral salpingo-oophorectomy.
Drawing on current practice and expert opinion, this study has provided evidence of the key messages required by affected women about BRCA1/BRCA2 and the optimal timing of communication. The findings will be helpful in developing new approaches to the delivery of information as genetic testing becomes further integrated into mainstream oncology services.
